Update on GSK744 and Monthly HIV Treatment or PrEP
March 14, 2014
For months, we've been excited about emerging data regarding GSK744 (also known as "744"), an investigational integrase inhibitor, close cousin of dolutegravir (Tivicay, DTG), with the potential for once-monthly injection dosing and promise in pre-exposure prophylaxis (PrEP) -- at least in rectally-exposed monkeys. Indeed, adherence concerns remain prominent in both of these therapeutic areas, concerns that could be readily addressed by directly observed, injectable treatments.
Data presented at CROI 2014 continued to fuel this fire. First, investigators showed that once-monthly injections of 744 provided 100% protection (in monkeys) from repeated intravaginal challenge from SHIV.View Full Article
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)